You do not have JavaScript Enabled on this browser. Please enable it in order to use the full functionality of our website.

EBP Compendium: Summary of Clinical Practice Guideline

American Academy of Neurology; National Parkinson Foundation; Parkinson's Disease Foundation
Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review)

Miyasaki, J. M., Shannon, K., et al. (2006).
Neurology, 66(7), 996–1002.

AGREE Rating: Highly Recommended


This is a guideline and corresponding review from the American Academy of Neurology. This guideline provides recommendations for effective assessment tools to screen for depression, psychosis and dementia in patients with Parkinson’s disease (PD). The target audience of this guideline includes clinicians involved in the care of patients with PD. Recommendations are graded A, B, C, or U based on the strength of supporting evidence. Level A recommendations are based on at least two Class I trials. Level B recommendations are based on one Class I trial or two Class II studies and Level C recommendations are based on one Class II study or two consistent Class III studies. Recommendations based on evidence from uncontrolled studies, case series, case reports, or expert opinion (Level U Evidence) is given when data is inadequate or conflicting. 


  • Assessment/Diagnosis
    • Assessment Instruments
      • Cognitive-Communication
        • “[T]he Mini-Mental State Examination (MMSE) and Cambridge Cognitive Examination (CAMCog) should be considered as screening tools for dementia in patients with Parkinson's disease" (Level B Evidence) (p. 999).
        • “The MMSE is as sensitive as the CAMCog and quicker to administer, but less specific” (p. 999).

Keywords: Dementia; Parkinson's Disease

Access the Guideline

Added to Compendium: November 2010

ASHA Corporate Partners